Using partition designs to enhance purification process understanding

Biotechnology and Bioengineering

Volumn 107, Issue 5, 2010, Pages 814-824

  Pieracci, John ^a   Perry, Leonard ^b   Conley, Lynn ^a  

^a BIOGEN   (United States)

^b UNIVERSITY OF SAN DIEGO   (United States)

Author keywords

Chromatography; Design space; Monoclonal antibody purification; Partition designs; Process development; Statistical design of experiments

Indexed keywords

DESIGN SPACE; MONOCLONAL ANTIBODY PURIFICATION; PARTITION DESIGNS; PROCESS DEVELOPMENT; STATISTICAL DESIGN OF EXPERIMENTS;

CHROMATOGRAPHY; MONOCLONAL ANTIBODIES; PURIFICATION; STATISTICS; SURFACE PLASMON RESONANCE;

DESIGN OF EXPERIMENTS;

MONOCLONAL ANTIBODY;

ARTICLE; COMPARATIVE STUDY; EXPERIMENTAL DESIGN; PROCESS DESIGN; PROCESS DEVELOPMENT; PURIFICATION;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOTECHNOLOGY; CHO CELLS; CRICETINAE; CRICETULUS; MODELS, THEORETICAL; TECHNOLOGY, PHARMACEUTICAL;

EID: 77958577706     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.22866     Document Type: Article

References (27)

1. Abu-Absi S, Yang L, Thompson P, Jiang C, Kandula S, Schilling B, Shukla A. 2010. Defining process design space for monoclonal antibody cell culture. Biotechnol Bioeng 106: 894-905.
2. Blank G. 2008. QbD: Integrating Regulatory Innovation With Good Science. Recovery of Biological Products XIII Conference, Quebec City, Quebec, Canada.
3. Cecchini D. 2009. Applications of design space for biopharmaceutical purification processes. In: Rathore AS, editors. Quality by Design for Biopharmaceuticals: Perspectives and Case Studies. Hoboken: Wiley Interscience, p. 127.
4. Coleman D, Montgomery D. 1993. Systematic approach to planning for a designed industrial experiment. Technometrics 35: 1-27.
5. Follman D, Fahrner R. 2004. Factorial screening of antibody purification processes using three chromatography steps without protein-A. J Chrom A 1024: 79-85.
6. Gardner A, Smith T. 2000. Identification and establishment of operating ranges of critical process variables. In: Sofer GZD, editor. Biopharmaceutical Process Validation. New York: Marcel Dekker, Inc., p. 61.
7. Grzeskowiak J, Tscheliessnig A, Toh P, Chusainow J, Lee Y, Wong N, Jungbauer A. 2009. 2-D DIGE to expedite downstream process development for human monoclonal antibody production. Protein Expression and Purification 66: 58-65.
8. Haimes Y. 1998. Risk Modeling, Assessment and Management. New York: John Wiley and Sons, Inc.
9. Harms J, Wang X, Kim T, Yang X, Rathore A. 2008. Defining design space for biotech products: case study of Pichia pastoris fermentation. Biotechnol Prog 24: 655-662.
10. ICH Q8(R1). 2008. Harmonized Tripartite Guideline on Pharmaceutical Development.
11. ICH Q9. 2005. Harmonized Tripartite Guideline on Quality Risk Management.
12. Jin M, Szapiel N, Zhang J, Hickey J, Ghose S. 2009. Profiling of host cell protein by two-dimensional difference gel electrophoresis (2D-DIGE):implications for downstream process development. Biotechnol Bioeng 105(2): 306-316.
13. Kelley B. 2000. Establishing process robustness using designed experiments. In: Sofer GZD, editor. Biopharmaceutical Process Validation. New York: Marcel Dekker, Inc., p. 29.
14. Li F, Hashimura Y, Pendleton R, Harms J, Collins E, Lee B. 2006. A systematic approach for scale-down model development and characterization of commercial cell culture processes. Biotechnol Prog 22: 696-703.
15. Montgomery D. 2009. Design and Analysis of Experiments. Hoboken, NJ: John Wiley & Sons.
16. Perry L, Montgomery D, Fowler J. 2001a. Partition experimental designs for sequential processes: Part I-First-order models. Qual Reliab Eng Int 17: 10.
17. Perry L, Montgomery D, Fowler J. 2001b. Partition experimental designs for sequential processes: Part II-Second-order models. Qual Reliab Eng Int 18: 10.
18. Perry L, Montgomery D, Fowler J. 2007. A partition experimental design for a sequential process with a large number of variables. Qual Reliab Eng Int 23: 10.
19. Pieracci J, Westoby M, Conley L, Notarnicola S, Cecchini D, Thommes J. 2008. Building Quality by Design into a Late Stage Antibody Process. Recovery of Biological Products XIII Conference, Quebec City, Quebec, Canada.
20. Rathore A, Branning R, Cecchini D. 2007. Design Space for Biotech Products. Biopharm Int 20: 36-40.
21. Rathore A, Winkle H. 2009. Quality by design for pharmaceuticals: regulatory perspective and approach. Nat Biotechnol 27: 26-34.
22. Romero J, Chrostowski J, Vilmorin P, Case J. 2006. Method of isolating biomacromolecules using low pH and divalent cations. U.S Patent Application #855, 734. U.S Patent and Trademark Office.
23. Shukla A, Hinckley P. 2008. Host cell protein clearance during protein-A chromatography: development of an improved column wash step. Biotechnol Prog 24: 1115-1121.
24. Shukla A, Jiang C, Ma J, Rubacha M, Flansburg L, Lee S. 2008. Demonstration of robust host cell protein clearance in biopharmaceutical downstream processes. Biotechnol Prog 24: 615-622.
25. Shukla A, Sorge L, Boldman J. 2001. Process characterization for metal affinity chromatography of an Fc fusion protein: a design-of-experiments approach. Biotechnol Appl Biochem 34: 71-80.
26. Streefland M, Van Herpen P, Van de Waterbeemd B, Van der Pol L, Beuvery E, Tramper J, Martens D, Toft M. 2009. A practical approach for exploration and modeling of the design space of a bacterial vaccine cultivation process. Biotechnol Bioeng 104: 592-604.
27. Westoby M, Haverstock R, Lam Y, Conley L, Thommes J. 2008. Application of Design Space Methodology to a Multi-Scale Centrifugation Harvest Operation with pH Induced Impurity Precipitation and Flocculation. Recovery of Biological Products XIII Conference, Quebec City, Quebec, Canada.